Generate Biomedicines Inc.
GENB | NASDAQ
$13.41
-$1.05 (-7.26%)
Nov 2, 2026, 1:44 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 |
|---|---|---|---|
Cash & Equivalents | 135.36M | 160.58M | 121.99M |
Short-Term Investments | 322.06M | 356.07M | 99.85M |
Long-Term Investments | n/a | n/a | n/a |
Other Long-Term Assets | 9.06M | 4.74M | 6.81M |
Receivables | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a |
Other Current Assets | 12.84M | 18.75M | 12.53M |
Total Current Assets | 470.25M | 535.39M | 234.37M |
Property-Plant & Equipment | 82.38M | 85.6M | 89.01M |
Goodwill & Intangibles | n/a | n/a | n/a |
Total Long-Term Assets | 91.44M | 90.35M | 95.82M |
Total Assets | 561.69M | 625.74M | 330.18M |
Account Payables | 5.65M | 7.62M | 3.84M |
Deferred Revenue | 12.17M | 17.24M | 21.19M |
Short-Term Debt | n/a | 14.26M | 15.01M |
Other Current Liabilities | 10.5M | 14.92M | 16.43M |
Total Current Liabilities | 56.64M | 58.39M | 82.2M |
Long-Term Debt | n/a | n/a | 53.52M |
Other Long-Term Liabilities | n/a | n/a | 813.15M |
Total Long-Term Liabilities | 49.01M | 52.55M | 871.18M |
Total Liabilities | 105.65M | 110.94M | 953.38M |
Total Debt | 62.63M | 65.57M | 68.53M |
Book Value | 456.05M | 514.8M | n/a |
Book Value Per Share | 3.56 | 4.02 | n/a |
Common Stock | 128K | 128K | 33K |
Retained Earnings | -804.99M | -737.74M | -676.29M |
Comprehensive Income | -129K | 24K | 106K |
Shareholders Equity | 456.05M | 514.8M | -615.97M |
Total Investments | 322.06M | 356.07M | 99.85M |
Add to Watchlist
Select watchlists to add or remove GENB